Breaking News

Matica Bio Opens New Cell and Gene Therapy GMP Facility

The 45,000 sq. ft. facility in Texas to produce viral vectors and cell-based products used in cell and gene therapies, vaccines and oncolytic therapies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, has opened its new 45,000 square foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines. Building on years of cell and gene therapy expertise, Matica Bio’s new facility is now expanding its capacity as a CDMO and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters